155 related articles for article (PubMed ID: 9704936)
1. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Suruga Y; Makino M; Okada Y; Tanaka H; De Clercq E; Baba M
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):316-22. PubMed ID: 9704936
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphonomethoxypropyl)adenine.
Rossi L; Serafini S; Franchetti P; Casabianca A; Orlandi C; Schiavano GF; Carnevali A; Magnani M
J Antimicrob Chemother; 2002 Nov; 50(5):639-47. PubMed ID: 12407119
[TBL] [Abstract][Full Text] [Related]
3. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice.
Balzarini J; Vahlenkamp T; Egberink H; Hartmann K; Witvrouw M; Pannecouque C; Casara P; Navé JF; De Clercq E
Antimicrob Agents Chemother; 1997 Mar; 41(3):611-6. PubMed ID: 9056002
[TBL] [Abstract][Full Text] [Related]
5. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
[TBL] [Abstract][Full Text] [Related]
6. Effects of Z-100, a Mycobacterium-tuberculosis-derived arabinomannan, on the LP-BM5 murine leukemia virus infection in mice.
Sasaki H; Kobayashi M; Pollard RB; Suzuki F
Pathobiology; 2001; 69(2):96-103. PubMed ID: 11752903
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS.
Klinman DM; Krieg A; Conover J; Ussery MA; Black PL
AIDS Res Hum Retroviruses; 1992 Jan; 8(1):101-6. PubMed ID: 1310603
[TBL] [Abstract][Full Text] [Related]
8. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.
Balzarini J; Aquaro S; Perno CF; Witvrouw M; Holý A; De Clercq E
Biochem Biophys Res Commun; 1996 Feb; 219(2):337-41. PubMed ID: 8604988
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Mulato AS; Cherrington JM
Antiviral Res; 1997 Nov; 36(2):91-7. PubMed ID: 9443665
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates.
Gong YF; Marshall DR; Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1683-7. PubMed ID: 7979311
[TBL] [Abstract][Full Text] [Related]
11. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.
Gangemi JD; Cozens RM; De Clercq E; Balzarini J; Hochkeppel HK
Antimicrob Agents Chemother; 1989 Nov; 33(11):1864-8. PubMed ID: 2482011
[TBL] [Abstract][Full Text] [Related]
12. Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir).
Zídek Z; Franková D; Holý A
Eur J Pharmacol; 1999 Jul; 376(1-2):91-100. PubMed ID: 10440094
[TBL] [Abstract][Full Text] [Related]
13. ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytes.
Bilello JA; Kort JJ; MacAuley C; Fredrickson TN; Yetter RA; Eiseman JL
J Acquir Immune Defic Syndr (1988); 1992; 5(6):571-6. PubMed ID: 1316959
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Tsai CC; Emau P; Follis KE; Beck TW; Benveniste RE; Bischofberger N; Lifson JD; Morton WR
J Virol; 1998 May; 72(5):4265-73. PubMed ID: 9557716
[TBL] [Abstract][Full Text] [Related]
15. Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model.
Hatse S; Naesens L; De Clercq E; Balzarini J
Biochem Pharmacol; 1998 Oct; 56(7):851-9. PubMed ID: 9774147
[TBL] [Abstract][Full Text] [Related]
16. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
De Clercq E
Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
Suo Z; Johnson KA
J Biol Chem; 1998 Oct; 273(42):27250-8. PubMed ID: 9765248
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate.
Fraternale A; Casabianca A; Tonelli A; Vallanti G; Chiarantini L; Brandi G; Celeste AG; Magnani M
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):209-20. PubMed ID: 10839656
[TBL] [Abstract][Full Text] [Related]
19. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.
Zídek Z; Franková D; Holý A
Antimicrob Agents Chemother; 2001 Dec; 45(12):3381-6. PubMed ID: 11709312
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
